Zacks Investment Research upgraded shares of HTG Molecular Diagnostics (NASDAQ:HTGM) from a hold rating to a buy rating in a research report released on Wednesday. The brokerage currently has $3.75 price objective on the medical research company’s stock.

According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “

Several other equities analysts also recently commented on the stock. ValuEngine raised shares of HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research note on Monday, October 23rd. HC Wainwright set a $6.00 price objective on shares of HTG Molecular Diagnostics and gave the company a buy rating in a research note on Wednesday, December 27th. Finally, Canaccord Genuity increased their price objective on shares of HTG Molecular Diagnostics to $5.00 in a research note on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $5.19.

Shares of HTG Molecular Diagnostics (HTGM) traded up $0.34 during trading hours on Wednesday, reaching $3.71. 1,273,200 shares of the company traded hands, compared to its average volume of 3,258,619. The company has a market cap of $38.58 and a P/E ratio of -1.45. HTG Molecular Diagnostics has a fifty-two week low of $1.20 and a fifty-two week high of $13.25.

A hedge fund recently raised its stake in HTG Molecular Diagnostics stock. Vanguard Group Inc. boosted its stake in HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 38.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 135,234 shares of the medical research company’s stock after purchasing an additional 37,841 shares during the period. Vanguard Group Inc. owned about 1.42% of HTG Molecular Diagnostics worth $359,000 at the end of the most recent quarter. 15.15% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “HTG Molecular Diagnostics (HTGM) Lifted to “Buy” at Zacks Investment Research” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/htg-molecular-diagnostics-htgm-lifted-to-buy-at-zacks-investment-research/1803513.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.